India’s recovery rate crosses 90%, sharpest weekly drop in Covid figures

In the steepest weekly fall yet in Covid-19 numbers in India, fresh infections recorded this week (October 19-25) were nearly 16% less than the previous week’s tally while deaths from the virus fell by 19% during this period.

India recorded just over 3.6 lakh fresh cases during the week, the lowest in absolute terms in three months (since 3.2 lakh were detected in the July 20-26 week), as per data collated from state governments.

This marked a drop of 15.7% from the previous week’s numbers, the sharpest weekly fall in cases since the pandemic hit India. Last week, nearly 4.3 lakh cases were recorded in the country.

While many countries in the West have been reporting record numbers of new coronavirus infections in the last few days, the cases have continued to decline in India. On Saturday, about 50,000 new infections were detected in the country, the lowest since July 28, barring the big dip this past Monday.

For the 22nd consecutive day, more people recovered from the disease than fell ill, a trend that has resulted in a significant decline in active cases in the country. As on Saturday, there were just about 6.68 lakh active cases, down from over ten lakh a month ago.

The buzz around an imminent covid-19 vaccine has raised hopes of a way back to normalcy for the billions affected by the pandemic around the world, said Kiran Mazumdar-Shaw, chairperson and managing director of Bengaluru-based Biocon Ltd. Mazumdar-Shaw is hopeful that the vaccine will be in India by June, but added delivering the vaccine to India’s over 1.2 billion population has its own challenges.

“I expect that by January, some of the other vaccines could be approved like AstraZeneca’s or one of our own Indian vaccines like the one by Bharat Biotech. If we finish the clinical trials in the next 2-3 months, even those may be approved by January-February. So I would expect that in Q1FY22 we should have vaccines available in India and other parts of the world,” said Kiran Mazumdar-Shaw in an interview to Mint.